Volume 73, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


We used an isotopic drug sensitivity assay to assess the sensitivity of isolates collected in Bangui, Central African Republic between March and July 2004. We tested antimalarials that are currently in use in this country (chloroquine, amodiaquine, quinine, and pyrimethamine), antimalarials that will become available in this region in the future (artemisinin and halofantrine), and prophylactic antimalarials (mefloquine, doxycycline, and atovaquone). The proportions of resistant isolates were 37% for chloroquine, 15.9% for amodiaquine, 0% for quinine, 0% for dihydroartemisinin, 1.6% for mefloquine, 3.8% for halofantrine, 4.0% for atovaquone, and 38.3% for pyrimethamine. No multi-resistant isolates (showing resistance to more than three drugs) were found. A positive correlation was found between the 50% inhibitory concentrations values for the following drugs: chloroquine and amodiaquine; quinine and halofantrine; chloroquine and dihydroartemisinin; chloroquine and halofantrine; amodiaquine and dihydroartemisinin; dihydroartemisinin and mefloquine; chloroquine and quinine; and quinine and dihydroartemisinin. These findings suggest that the Ministry of Health should recommend a interim policy with the amodiaquine plus sulfadoxine-pyrimethamine combination as the first-line antimalarial drug in Bangui until better alternative treatments such as artemisinin-based combination therapies become available at low prices in the Central African Republic.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. WHO, 2003. African Malaria Report. Geneva: World Health Organization. WHO/CDS/MAL/2003.1093. http://rbm.who.int/publications.
  2. Pierce PF, Milhous WK, Campbell CC, 1987. Clinical and laboratory characterization of a chloroquine-resistant Plasmodium falciparum strain acquired in the Central African Republic. Am J Trop Med Hyg 36 : 1–2. [Google Scholar]
  3. Belec L, Delmont J, Vesters I, Testa J, Christian KS, Georges AJ, 1988. Emergence of multiresistant Plasmodium falciparum malaria in Central African Republic. Presse Med 17 : 2090–2091. [Google Scholar]
  4. Menard D, Madji N, Manirakiza A, Djalle D, Koula MR, Talarmin A, 2005. Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquinesulfadoxine-pyrimethamine combination in central African children with non-complicated malaria. Am J Trop Med Hyg 72 : 581–585. [Google Scholar]
  5. Ministère du plan et de la coopération internationale, UNICEF, 2001. Enquête à indicateurs multiples, MICS 2000, Rapport final Bangui Avril 2001. BBA Editions: 130–131
  6. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16 : 710–718. [Google Scholar]
  7. Le Bras J, Ringwald P, 1990. Plasmodium falciparum chemore-sistance. The situation in Africa in 1989. Med Trop (Mars) 50 : 11–16. [Google Scholar]
  8. Le Bras J, Simon F, Ramanamirija JA, Calmel MB, Hatin I, Deloron P, Porte J, Marchais H, Clausse JL, Biaud JM, 1987. Sensitivity of Plasmodium falciparum to quinolines and therapeutic strategies: comparison of the situation in Africa and Madagascar between 1983 and 1986. Bull Soc Pathol Exot 80 : 477–489. [Google Scholar]
  9. Basco LK, Le Bras J, 1994. In vitro susceptibility of Cambodian isolates of Plasmodium falciparum to halofantrine, pyronaridine and artemisinin derivatives. Ann Trop Med Parasitol 88 : 137–144. [Google Scholar]
  10. Hatin I, Trape JF, Legros F, Bauchet J, Le Bras J, 1992. Susceptibility of Plasmodium falciparum strains to mefloquine in an urban area in Senegal. Bull World Health Organ 70 : 363–367. [Google Scholar]
  11. Basco LK, Le Bras J, 1992. In vitro activity of halofantrine and its relationship to other standard antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 47 : 521–527. [Google Scholar]
  12. Gay F, Bustos D, Traore B, Jardinel C, Southammavong M, Ciceron L, Danis M, 1997. In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. Am J Trop Med Hyg 56 : 315–317. [Google Scholar]
  13. Basco LK, Eldin de Pecoulas P, Wilson CM, Le Bras J, Mazabraud A, 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 69 : 135–138. [Google Scholar]
  14. Mezui Me Ndong J, Atteke C, Aubouy A, Bakary M, Lébibi J, Deloron P, 2003. In vitro activity of chloroquine, quinine, mefloquine and halofantrine against Gabonese isolates of Plasmodium falciparum. Trop Med Int Health 8 : 25–29. [Google Scholar]
  15. Ringwald P, Bickii J, Basco LK, 1999. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg 61 : 187–192. [Google Scholar]
  16. Bergeri I, Zoguereh DD, Madji N, Barrau K, Delmont J, Namsenmo A, Ndoyo J, 2003. In vivo evaluation of chloroquine therapeutic efficacy in uncomplicated Plasmodium falciparum malaria in Central African Republic in 1997 and 1998. Bull Soc Pathol Exot 96 : 29–34. [Google Scholar]
  17. Carme B, Gay F, Ndounga M, Hayette-Gorremans MP, Bouquety JC, 1995. In vitro drug sensitivity and clinical aspects of Plasmodium falciparum malaria in African children. Trop Med Parasitol 46 : 270–274. [Google Scholar]
  18. Ouedraogo JB, Dutheil Y, Tinto H, Traore B, Zampa H, Tall F, Coulibaly SO, Guiguemde TR, 1998. In vitro sensitivity of Plasmodium falciparum to halofantrine compared with chloroquine, quinine and mefloquine in the region of Bobo-Dioulasso, Burkina Faso (West Africa). Trop Med Int Health 3 : 381–384. [Google Scholar]
  19. Ringwald P, Bickii J, Basco LK, 1996. In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg 55 : 254–258. [Google Scholar]
  20. Pradines B, Mabika Mamfoumbi M, Parzy D, Owono Medang M, Lebeau C, Mourou Mbina JR, Doury JC, Kombila M, 1998. In vitro susceptibility of Gabonese wild isolates of Plasmodium falciparum to artemether, and comparison with chloroquine, quinine, halofantrine and amodiaquine. Parasitology 117 : 541–545. [Google Scholar]
  21. Philipps J, Radloff PD, Wernsdorfer W, Kremsner PG, 1998. Follow-up of the susceptibility of Plasmodium falciparum to antimalarials in Gabon. Am J Trop Med Hyg 58 : 612–618. [Google Scholar]
  22. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV, 2003. Re-emergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187 : 1870–1875. [Google Scholar]
  23. Hyde JE, 2002. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect 4 : 165–174. [Google Scholar]
  24. Thanh NV, Cowman AF, Hipgrave D, Kim TB, Phuc BQ, Cong LD, Biggs BA, 2001. Assessment of susceptibility of Plasmodium falciparum to chloroquine, quinine, mefloquine, sulfadoxine-pyrimethamine and artemisinin in southern Vietnam. Trans R Soc Trop Med Hyg 95 : 513–517. [Google Scholar]
  25. Noedl H, Faiz MA, Yunus EB, Rahman MR, Hossain MA, Samad R, Miller RS, Pang LW, Wongsrichanalai C, 2003. Drug-resistant malaria in Bangladesh: an in vitro assessment. Am J Trop Med Hyg 68 : 140–142. [Google Scholar]
  26. Basco LK, Le Bras J, 1993. In vitro activity of artemisinin derivatives against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 49 : 301–307. [Google Scholar]
  27. Bustos MDG, Gay F, Diquet B, 1994. In vitro tests on Philippine isolates of Plasmodium falciparum against four standard antimalarials and four qinghaosu derivatives. Bull World Health Organ 72 : 729–735. [Google Scholar]
  28. Pradines B, Rogier C, Fusai T, Tall A, Trape JF, Doury JC, 1998. In vitro activity of artemether against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial drugs. Am J Trop Med Hvg 58 : 354–357. [Google Scholar]
  29. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, O’Neill PM, Bray PG, Ward SA, Krishna S, 2003. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424 : 957–961. [Google Scholar]

Data & Media loading...

  • Received : 04 Oct 2004
  • Accepted : 19 Jan 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error